February 2026 — Where Things Stand
As of February 2026, the Tylenol autism litigation is active on three fronts simultaneously. First, the Second Circuit appeal of MDL-3043's August 2024 dismissal is pending. Oral arguments were held November 17, 2025, with a ruling expected within 6 to 12 months. Second, California state court cases in Alameda County are proceeding under the Kelly-Frye standard with active pretrial litigation. Third, Illinois state court cases in St. Clair, Madison, and Cook counties continue under the Frye standard. New claimants are being evaluated and enrolled by plaintiff's firms across all three litigation tracks. The window to enroll before the Second Circuit ruling — which may create a surge of new filings — is open now.
November 2025 — Second Circuit Oral Arguments
The Second Circuit heard oral arguments on November 17, 2025 in the appeal of Judge Denise Cote's August 2024 Daubert dismissal of MDL-3043. Two of the three appellate judges openly questioned whether the district court had acted too aggressively — asking whether a blanket MDL-wide Daubert exclusion was consistent with Supreme Court precedent, and whether individual case-specific evidence should have been permitted to survive even if some expert theories were excluded. Legal analysts who attended the argument described the questioning as unusually pointed and skeptical of the MDL dismissal. A ruling is expected in 2026.
September 2025 — HHS and RFK Jr. Prenatal Acetaminophen Report
On September 22, 2025, HHS Secretary Robert F. Kennedy Jr. released a report identifying prenatal acetaminophen and folate deficiency as contributors to rising autism rates in the United States. The Trump administration directed the FDA to evaluate updating acetaminophen product labeling to include prenatal warnings. This government-level validation is legally significant for plaintiffs' Frye-standard arguments in California and Illinois: when the U.S. Secretary of Health endorses the prenatal-acetaminophen-autism connection, defendants face a much harder argument that the scientific methodology is not generally accepted in the relevant community.
October 2025 — Texas AG Sues Johnson & Johnson and Kenvue
Texas Attorney General Ken Paxton filed suit against Johnson & Johnson and Kenvue in October 2025, alleging failure to warn about the prenatal risks of acetaminophen. The suit is a government enforcement action — not a vehicle for private plaintiff recovery — but it adds governmental pressure on the defendants and generates significant news coverage in Texas, where awareness of the lawsuit is now high. Note: Texas's pharmaceutical safe harbor law complicates private plaintiff claims in Texas courts; families in Texas should consult an attorney before attempting to file in Texas state court.
Frequently Asked Questions
Related Pages
Tylenol Liver Damage Lawsuit
Acetaminophen — the active ingredient in Tylenol — is the leading cause of acute liver failure in the United States, responsible for approximately 56,000 emergency room visits, 26,000 hospitalizations, and nearly 500 deaths each year. Lawsuits allege that McNeil Consumer Healthcare and parent company Johnson & Johnson failed to adequately warn consumers about the narrow margin between a therapeutic dose and a potentially fatal overdose. Even doses only slightly above the recommended amount, especially when combined with alcohol use or taken across multiple acetaminophen-containing products, can cause catastrophic liver damage. If you or a loved one suffered acute liver failure, liver transplant, or death linked to acetaminophen use, you may be eligible for compensation. These liver damage claims are separate from the Tylenol autism/ADHD litigation — they involve direct injury to the person who took the medication.
Learn moreLearn moreLearn moreLearn moreLearn moreLearn moreLearn moreTylenol Autism Lawsuit Lawsuit
Acetaminophen — sold under the brand name Tylenol by Kenvue (formerly Johnson & Johnson) and as dozens of store-brand generics by Walmart, CVS, Walgreens, Target, Costco, Meijer, and others — was the most commonly used pain reliever during pregnancy in the United States for decades. Starting with a landmark 2018 American Journal of Epidemiology meta-analysis of 130,000 mother-child pairs, and culminating in a 2021 consensus statement signed by 91 scientists published in Nature Reviews Endocrinology, accumulating evidence linked prolonged prenatal acetaminophen exposure to significantly elevated risks of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). The federal multidistrict litigation, MDL-3043 (In re Acetaminophen — ASD/ADHD Products Liability Litigation) in the Southern District of New York, was dismissed in August 2024 after Judge Denise L. Cote excluded all plaintiffs' general causation experts under the Daubert standard. Critically, the Second Circuit Court of Appeals heard oral arguments on November 17, 2025 — and two of the three judges on the panel openly questioned whether Judge Cote acted too aggressively in excluding the expert testimony. A reversal by the Second Circuit could reinstate thousands of federal cases. Separately, California state courts (Alameda County) and Illinois state courts (St. Clair, Madison, and Cook counties) have active acetaminophen-autism cases proceeding under the Frye admissibility standard, which does not apply the same gatekeeping test that closed the federal MDL. Store-brand acetaminophen users have the same legal claims as Tylenol brand users — the failure-to-warn theory applies equally to Walmart's Equate brand, CVS Health brand, Walgreens brand, Costco Kirkland brand, and all other private-label acetaminophen products.
View full case overview